The Spanish Government authorized the purchase of ten units of proton therapy equipment for the National Health System

01

Aug 2022

On July 5, 2022, it was announced by the Ministry of Health that the Council of Ministers authorized the tender for the purchase of ten units of equipment for the treatment with proton therapy and associated electromedical equipment for an estimated value of €271 million (VAT included). The cost of the equipment will be financed by the Amancio Ortega Foundation.

This equipment is intended for public hospitals of the National Health System (SNS) in seven Autonomous Communities within the Proton therapy Implementation Plan for the treatment of tumors, especially in pediatric patients. Proton therapy equipment will be provided at the rates of:

  • One unit for the Basque Country, Galicia, Valencian Community, and the Canary Islands;
  • Two units for the Community of Madrid, Andalusia, and Catalonia.

With this agreement, the Proton therapy Implementation Plan of the SNS is distributed in four annuities: €28 million in 2022; €24.3 million in 2023; €121.5 million in 2024; and €97.2 million in 2025.

The full details in Spanish can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

17

Jun 2022

On May 31, 2022, it was announced by the Ministry of Health that the Council of Ministers authorized the distribution of almost €400 million for the renovation of high-tech equipment in the National Health System (SNS) through the High-End Technology Equipment Investment Plan (INVEAT) of the SNS.

Read more

25

May 2022

On April 25, 2022, the Decision Forum for "New Method" recommended not to use the endobronchial valve (Zephyr) to reduce lung volume in severe emphysema treatment, as there was no evidence of the long-term effectiveness. The method can be used in the context of clinical studies.

Read more

19

May 2022

On April 25, 2022, the Decision Forum for "New Method" did not prioritize any surgical procedure in the treatment of morbid obesity. Available evidence in the complete method assessment shows minor or no difference in weight loss, diabetes control, or health-related quality of life when using various surgical procedures. The comparative effect on the risk of early mortality, progression of obesity, and obesity-related comorbidities was not possible to determine. The cost differences are non-significant. Further research was recommended.

Read more

10

May 2022

A new test called Genedrive System to detect babies at risk of gentamycin-related deafness was developed at the University of Manchester, funded by the National Institute for Health and Care Research (NIHR). On April 02, 2022, NHS England and NHS Improvement announced that Genedrive is now fully CE certified to be used in a clinical setting. The test is expected to be implemented in routine care in all NHS Manchester Foundation Trust hospitals within several weeks.

Read more

03

May 2022

On April 12, 2022, NHS England and NHS Improvement (NHSE/I) published 2022/23 priorities and operational planning guidance, including elective recovery planning supporting guidance, capital guidance for 2022-25, and revenue finance and contracting guidance. The 2022/23 priorities and operational planning guidance set out NHSE/I priorities for the year ahead and reconfirms the ongoing need to restore services, meet new care demands, and reduce the care backlogs that are a direct consequence of the pandemic.

Read more